.

.

Vetera Gold XP Single Dose

3583

Vetera Gold XP Single Dose

Boehringer Ingelheim - Equine Vaccine protects horses 4 months of age and older against Eastern and Western encephalomyelitis, rhinopneumonitis (Equine Herpesvirus types EHV-1 and EHV-4), influenza type A2, tetanus, and West Nile Virus.

$64.49
Quantity

Vetera Gold XP (West Nile + 2-way Sleeping Sickness + Tetanus + Flu + Rhino) Equine Vaccine protects horses 4 months of age and older against Eastern and Western encephalomyelitis, rhinopneumonitis (Equine Herpesvirus types EHV-1 and EHV-4), influenza type A2, tetanus, and West Nile Virus.

Vetera Gold XP aids in the reduction of respiratory disease and shedding caused by A2 Equine Influenza virus. Product contains Kentucky Lineage (KY/95), Florida sublineage clade 1 (OH/03), and Florida sublineage clade 2 (RI/07) equine influenza strains. Duration of immunity has been demonstrated for at least 6 months against OH/03. The duration of immunity against West Nile Virus is at least 12 months.

Species: horses

FEATURES / BENEFITS

Reduces the number of injections needed by protecting your horse against seven major infectious diseases in a single vaccine; it’s the only vaccine on the market to offer this level of protection. 

Provides immunity against Equine Influenza for at least 6 months and West Nile Virus for at least 12 months. 

Easy to administer; 7-way protection. 

Protects against the most common infectious diseases that affect horses. 

Meets all federal standards for safety and efficacy.

SPECIFICATIONS

Gentamicin and amphotericin B are used as preservatives. 

Store between 35 to 45 °F (2 to 7 °C). Protect from freezing. 

Do not vaccinate within 21 days before slaughter. 

Use entire contents when first opened. 

Anaphylactoid reactions may occur; administer epinephrine. 

Vaccinate normal, healthy, immunocompetent animals only. 

For veterinary use only.

INSTRUCTIONS

Shake well before use. Administer 1 ml, intramuscularly. Administer a second 1-ml dose 3 to 4 weeks later. Use a different injection site. Revaccinate annually and prior to anticipated exposure with a 1-ml dose.

INFORMATIONAL VIDEO

3583

Specific References

related products